[go: up one dir, main page]

AU2671795A - Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments - Google Patents

Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments

Info

Publication number
AU2671795A
AU2671795A AU26717/95A AU2671795A AU2671795A AU 2671795 A AU2671795 A AU 2671795A AU 26717/95 A AU26717/95 A AU 26717/95A AU 2671795 A AU2671795 A AU 2671795A AU 2671795 A AU2671795 A AU 2671795A
Authority
AU
Australia
Prior art keywords
fragments
cardiodilatin fragments
highly purified
cardiodilatin
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26717/95A
Inventor
Knut Adermann
Wolf-Georg Forssmann
Hansueli Immer
Christian Klessen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19513784A external-priority patent/DE19513784A1/en
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU2671795A publication Critical patent/AU2671795A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same.
AU26717/95A 1994-06-02 1995-05-30 Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments Abandoned AU2671795A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4420381 1994-06-02
DE4420381 1994-06-02
DE9513784 1995-04-10
DE19513784A DE19513784A1 (en) 1994-06-02 1995-04-10 High purity urodilatin and process for its manufacture
PCT/EP1995/002050 WO1995033769A1 (en) 1994-06-02 1995-05-30 Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments

Publications (1)

Publication Number Publication Date
AU2671795A true AU2671795A (en) 1996-01-04

Family

ID=25937342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26717/95A Abandoned AU2671795A (en) 1994-06-02 1995-05-30 Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments

Country Status (8)

Country Link
US (5) US5767239A (en)
EP (1) EP0763061B1 (en)
JP (2) JPH10500969A (en)
AT (1) ATE226960T1 (en)
AU (1) AU2671795A (en)
ES (1) ES2188665T3 (en)
IL (1) IL113979A0 (en)
WO (1) WO1995033769A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763061B1 (en) * 1994-06-02 2002-10-30 Forssmann, Wolf-Georg, Prof. Dr. med. Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
KR100691545B1 (en) * 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 Eye drops for promoting lacrimal fluid secretion or treating corneal conjunctival disorders using sodium diuretic peptide as an active ingredient
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
DK1759001T3 (en) 2004-04-21 2011-08-01 Enobia Pharma Inc Conjugate for Bone Delivery and Method of Preparation by Targeting Proteins to the Bone
DK1709065T3 (en) * 2004-10-04 2010-08-23 Novetide Ltd Modion exchange method for peptides
PT2510942E (en) 2005-04-07 2015-12-28 Cardiorentis Ag Use of natriuretic peptide for treating heart failure
EP2171053B1 (en) * 2007-07-20 2014-04-23 Mayo Foundation for Medical Education and Research Natriuretic polypeptides
US20090163421A1 (en) * 2007-12-19 2009-06-25 Ekr Therapeutics, Inc. Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
JP6108858B2 (en) 2012-02-17 2017-04-05 株式会社半導体エネルギー研究所 P-type semiconductor material and semiconductor device
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EA201500765A1 (en) 2013-01-25 2015-12-30 Кардиорентис Лтд. METHODS OF TREATING CARDIOVASCULAR DISEASES
CN103145827A (en) * 2013-03-04 2013-06-12 吉尔生化（上海）有限公司 Solid-phase synthesis method of ularitide
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (en) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat subjects with alkaline phosphatase deficiency
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (en) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for treating cranial suture early healing disease in a patient
CN106928342B (en) * 2015-12-31 2020-10-16 深圳翰宇药业股份有限公司 Preparation method of ularitide
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASIA IN ADOLESCENTS AND ADULTS
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20240158374A (en) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (en) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Glycoprotein production
WO2019227342A1 (en) * 2018-05-30 2019-12-05 深圳翰宇药业股份有限公司 Method for purifying long chain polypeptide
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN110845599B (en) * 2018-08-21 2022-10-14 鲁南制药集团股份有限公司 Preparation and purification method of polypeptide
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022029499A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
WO2022029497A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Ularitide for use in methods of treating refractory ascites
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3217598A1 (en) 2021-05-06 2022-11-10 Par Ingemar Johansson Diagnosing and treating critically ill subjects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
DE3346953A1 (en) * 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg CARDIODILATIN, A NEW PEPTIDE HORMONE AND METHOD FOR THE PRODUCTION THEREOF
EP0180615B1 (en) * 1984-04-19 1995-04-05 Scios Nova Inc. Novel atrial natriuretic/vasodilator polypeptides
JPH0672157B2 (en) * 1984-08-29 1994-09-14 味の素株式会社 New peptide
US5057603A (en) * 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
EP0349545B1 (en) * 1987-03-02 1993-02-03 FORSSMANN, Wolf-Georg, Prof. Dr. med. New cardiodilatin fragment, process for preparing same and use thereof
US5449751A (en) * 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5204327A (en) * 1988-11-18 1993-04-20 Ashi Kasei Kogyo Kabushiki Kaisha Treatment of cerebral edema with anp pharmaceutical compositions
EP0763061B1 (en) * 1994-06-02 2002-10-30 Forssmann, Wolf-Georg, Prof. Dr. med. Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments

Also Published As

Publication number Publication date
US20090240031A1 (en) 2009-09-24
EP0763061B1 (en) 2002-10-30
US20100317600A1 (en) 2010-12-16
JP2005298526A (en) 2005-10-27
US20030171536A1 (en) 2003-09-11
ATE226960T1 (en) 2002-11-15
WO1995033769A1 (en) 1995-12-14
EP0763061A1 (en) 1997-03-19
JPH10500969A (en) 1998-01-27
IL113979A0 (en) 1995-10-31
JP4130671B2 (en) 2008-08-06
ES2188665T3 (en) 2003-07-01
US5767239A (en) 1998-06-16
US20060122371A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
AU2671795A (en) Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
BG101384A (en) New pesticide proteins and strains
AU1378595A (en) Methods and compositions for increasing the benefits of Rhizobium inoculation to legume crop productivity
AU1155495A (en) Process for the preparation of non-cariogenic sugars
AU4712396A (en) Chiral methylphenyloxazolidinones
WO1995014038A3 (en) Purification of hemoglobin
AU5155996A (en) Control of pod dehiscence
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
HUT58764A (en) Process for producing peptides, pharmaceutical compositions containing them and amino-acid intermediates
AU3178997A (en) Method for producing xylitol
AU5265296A (en) Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
IL99079A0 (en) Protein structure of the plant toxin gelonin
NZ303588A (en) Mpl ligand analogs having one or more changed glycosylation sites uses for these ligand analogs and dna sequences encoding them
MX9806041A (en) PURIFIED SR-p70 PROTEIN.
WO1988003927A3 (en) Renin inhibitors
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
AUPM772494A0 (en) Improvements in production of proteins in host cells
CA2191407A1 (en) Process for using the yeast adh ii promoter system for the biotechnological production of heterologous proteins in high yields
AU1662495A (en) Skin package
EP1308514A3 (en) ICAM-4 Materials and Methods
MY105082A (en) Separation process
EP0816328A3 (en) Process for the manufacture of acetonylbenzamides
AU1811195A (en) Process for extracting highly purified, virus-inactivated alpha1-anti-trypsin by anion exchanger chromatography
AU6358096A (en) New immunoregulatory protein lst-1